Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Current Deferred Revenue (2020 - 2024)

Janux Therapeutics (JANX) has disclosed Current Deferred Revenue for 5 consecutive years, with $94000.0 as the latest value for Q2 2024.

  • On a quarterly basis, Current Deferred Revenue fell 98.24% to $94000.0 in Q2 2024 year-over-year; TTM through Jun 2024 was $94000.0, a 98.24% decrease, with the full-year FY2023 number at $1.7 million, down 68.46% from a year prior.
  • Current Deferred Revenue was $94000.0 for Q2 2024 at Janux Therapeutics, down from $972000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $8.0 million in Q4 2020 to a low of $94000.0 in Q2 2024.
  • A 5-year average of $4.4 million and a median of $5.1 million in 2021 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: grew 12.2% in 2022, then crashed 98.24% in 2024.
  • Janux Therapeutics' Current Deferred Revenue stood at $8.0 million in 2020, then plummeted by 35.46% to $5.2 million in 2021, then grew by 4.71% to $5.4 million in 2022, then crashed by 68.46% to $1.7 million in 2023, then plummeted by 94.49% to $94000.0 in 2024.
  • Per Business Quant, the three most recent readings for JANX's Current Deferred Revenue are $94000.0 (Q2 2024), $972000.0 (Q1 2024), and $1.7 million (Q4 2023).